Adult
Rifabutin
Warning
General Information
Restricted formulary antimicrobial: For details see OUH netFormulary
Renal and hepatic impairment
Dose in renal impairment
|
eGFR (mL/min/1.73m2) |
Oral dose |
|
more than 30 |
Dose as in normal renal function |
|
10-30 |
Use half of the normal dose. Maximum 300mg daily |
|
less than 10 |
Use half of the normal dose. Maximum 300mg daily |
|
HD/HDF/High Flux |
Dose as in eGFR less than 10ml/min/1.73m2. Not dialysed |
|
PD |
Dose as in eGFR less than 10ml/min/1.73m2. Unlikely to be dialysed |
Use in hepatic impairment
No dose adjustment required in mild hepatic impairment. Use with caution in severe hepatic impairment.
Pregnancy and breastfeeding
Discuss with pharmacy.
Additional information
- Rifabutin has many drug interactions. Contact a pharmacist for further advice.
- White blood cell, platelet counts and LFTs should be monitored periodically during treatment.
References
- Summary of Product Characteristics (SPC) for Mycobutin. Accessed via www.medicines.org.uk 26/03/18. Last updated 21/03/18
- The Renal Drug Database. Rifabutin. Accessed via renaldrugdatabase.com 26/03/18. Last updated 22/02/18
- BNF online accessed via www.medicinescomplete.com 14/1/19; last updated 11/12/18